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Introduction. Skin fragility and recurrent wounds are hallmarks of hereditary epidermolysis bullosa (EB). Treatment options to
accelerate wound healing are urgently needed. Oleogel-S10 contains a betulin-rich triterpene extract from birch bark. In this study,
we tested the wound healing properties of topical Oleogel-S10 in patients with dystrophic EB. Methods. We conducted an open,
blindly evaluated, controlled, prospective phase II pilot trial in patients with dystrophic EB (EudraCT number 2010-019945-24).
Healing of wounds treated with and without topical Oleogel-S10 was compared. Primary efficacy variable was faster reepithelial-
ization as determined by 2 blinded experts. The main secondary outcome variable of the study was percentage of wound epithe-
lialization. Results. Twelve wound pairs of 10 patients with dystrophic EB were evaluated. In 5 of 12 cases, both blinded reviewers
considered epithelialization of the interventionwounds as superior. In 3 cases, only one reviewer consideredOleogel-S10 as superior
and the other one as equal to control. Measurements of wound size showed a trend towards accelerated wound healing with the
intervention but without reaching statistical significance. Conclusion. Our results indicate a potential for faster reepithelialization
of wounds in patients with dystrophic EB when treated with Oleogel-S10 but larger studies are needed to confirm significance.
1. Introduction
Epidermolysis bullosa (EB) comprises a heterogeneous group
of inherited skin diseases characterized by skin fragility
leading to recurrent wounds [1, 2]. Cutaneous and extra-
cutaneous manifestations can result in severe morbidity
and a reduced life expectancy [3–6]. Particularly in the
generalized dystrophic EB subtypes, there is a significant risk
of developing aggressive squamous cell carcinomas, with an
increased incidence of metastases and death [7].
Up to now, no causal therapy in the sense of prevention
of blister formation or improvement of skin stability is
available. Treatment of EB mostly remains symptomatic [8]
with optimal wound care and protection of the skin being
the core therapeutic strategies. Wound care in these patients
usually follows the “wound bed preparation model” [9–11],
including the whole patient centered concerns [12], as well as
local wound factors such as reduction of bacterial load and
choice of optimal atraumatic dressings. Additional means to
accelerate wound healing are urgently needed [13].
Birch (Betula species) is a medical plant. Its bark has been
used as a natural remedy for skin diseases and wound care for
centuries [14, 15]. Oleogel-S10 is a semisolid gel, containing
10% triterpene dry extract (TE) from Betulae cortex (birch
bark) and refined sunflower oil (SFO) without the need for
further excipients [16].
Both components have a low potential for allergic sensiti-
zation and seem therefore suitable for use on wounds. To our
knowledge, over the course of 10 years, there have been 2 cases
of contact sensitization towards the triterpene extract, one of
them being published [17]. Both patients known to us showed
only a local skin reaction. No anaphylaxis has been reported.
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Figure 1: Healing of chronic wound on the ankle of a 12-year-old suffering from RDEB after 5 weeks of treatment with Oleogel-S10 (a-b).
Healing of chronic wound in the groin of a 50-year-old male after only 6 days of treatment with Oleogel-S10 (c-d).
Refined SFO is also considered to have a very low
potential for sensitization and is therefore often used as
a moisturizer in little children [18]. In an older study by
Halsey et al., SFO did not provoke a reaction when tested in
sunflower seed allergic patients [19].
Triterpenes were shown to enhance epidermal barrier
recovery and to stimulate wound healing [20–24]. In 2014,
Ebeling et al. published results around the molecular mech-
anism of the effects of birch bark on keratinocytes [25]. The
authors showed significantly accelerated reepithelialization in
a porcine ex vivo wound healing model when treating the
wound with Oleogel-S10 as compared to sunflower oil alone
or the oil in combinationwith a gelling agent (ethyl cellulose).
In the same model, this treatment led to an improvement
of barrier regeneration. Various mediators involved in the
inflammatory phase of wound healing were positively mod-
ulated, among them COX-2 and IL-6, the latter being known
for playing an important role inwoundhealing and epidermal
barrier repair [26, 27]. In addition, in vitro and in vivo
studies suggest that betulin has anticarcinogenic properties
and induces apoptosis in different tumor cells including
human squamous cell carcinoma (SCC) cells [28–31].
The ideal formulation of Oleogel-S10 has further been
examined by Steinbrenner et al. [32]. The group tested the
effect of different oils onwoundhealingwhen used alone or in
combination with TE. The majority of oils seemed to hinder
wound healing to some extent, SFO being among the least
impairing oils when used alone. However, when using SFO
with TE as in Oleogel-S10, wound healing was significantly
improved as compared to both sunflower oil (SFO) and SFO
with ethyl cellulose for an improved viscosity.
The effects of Oleogel-S10 have already been investigated
in vivo on different types of wounds where this treatment
seemed to promote wound healing and was very well
tolerated [33–35]. Additionally, a very recent randomized
controlled trial found enhanced epithelialization of split-
thickness skin graft donor site wounds after treatment with
Oleogel-S10 [22]. In 2016, Oleogel-S10 was approved in the
European Union as a new medicine for the treatment of
partial thickness wounds in adults (http://www.ema.europa
.eu/ema/index.jsp?curl=pages/medicines/human/medicines/
003938/human med 001956.jsp).
The results of these different reports were in keeping with
our own experiences from using Oleogel-S10 for wound care
of few individual patients suffering from different subtypes of
EB outside of a study setting (Figure 1).
In the present study, we investigated the effect of Oleogel-
S10 on wound healing in patients with dystrophic EB. We
hypothesized that Oleogel-S10 in combination with standard
nonadhesive wound dressings would lead to faster wound
healing as opposed to the use of standard wound care alone.
Furthermore, we assessed the feasibility of conducting a
larger trial in this patient group.
2. Methods
This study was designed as an open-label, prospective, con-
trolled, blindly evaluated, monocentric phase II pilot trial
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Figure 2: Study design.
to compare intraindividually the efficacy and tolerance of
Oleogel-S10 in combination with nonadhesive wound dress-
ing versus nonadhesive wound dressing alone (Figure 2).
The intraindividual comparison was chosen to minimize
the influence of age, health status, medications, and other
potentially confounding factors.
The study (EudraCT number 2010-019945-24) was con-
ducted in compliance with IEC, informed consent regula-
tions, and ICH and GCP guidelines and was approved by the
ethics committee of the University of Freiburg.
2.1. Patient Eligibility Criteria. Patients of any age beyond
infancy and with an immunochemically and/or genetically
proven diagnosis of hereditary EB and at least 1 wound
between 10 cm2 and 200 cm2 (alternatively 2 comparable
lesions of at least 5 cm2 each) were recruited for this study.
We differentiatedwounds that had appeared less than 6weeks
earlier and those with no tendency to heal for at least 6 weeks.
Children were deliberately included in this study, as they
represent a large proportion of our patients and optimized
wound healing would be of particular interest to them.
Patients were excluded from this study if they had been
on a systemic treatment with corticosteroids within the last
30 days or if they had taken any investigational drugs within
3 months before screening. They were also excluded if they
suffered from uncontrolled diabetes mellitus, diabetic ulcers,
or other diseases or conditions that could interfere with the
assessment of safety, tolerance, or efficacy of Oleogel-S10
during the study.
Patients or their legal representatives had to provide
written informed consent before participation in the study.
For this proof-of-concept study, we aimed to include 10
patients.
2.2. Intervention. Patients of all ages presenting at the EB-
Centre Freiburg for regular follow-up visits were screened
according to the study protocol. If the investigator iden-
tified a skin lesion (10 cm2 to 200 cm2) eligible for study
treatment, it was divided into two halves which were then
allocated to either the intervention or the treatment arm.
This method ensured a comparison between wound areas
in a similar anatomic location and within identical wound
healing phases. Alternatively, if there were two comparable
lesions (≥5 cm2 each) of similar size and shape, these were
selected and considered one wound pair. Wounds located at
sites of major trauma (e.g., elbows, knees, and buttocks) and
circumferential wounds were not included.
One half of thewoundwas chosen at random to be treated
with Oleogel-S10 (applied approximately at 1mm thickness)
and covered by a nonadhesive wound dressing (Mepilex
Transfer, Mo¨lnlycke Health Care, Sweden); the unwounded
skin next to this half as well as the border between the
wound halves was marked to ensure that Oleogel-S10 was
always applied to the same part of the wound. In other prior
studies, it had been shown that the product did not spread
to other areas than the ones it was applied to. Each wound
half was measured and the data were entered into a wound
surface-measuring program developed at our wound care
clinic (University of Freiburg, Department of Dermatology)
to ensure a comparable initial wound size. To serve as control,
the other half of the lesion was covered with a nonadhesive
wound dressing only (Mepilex Transfer, reference therapy). If
the investigator had identified two comparable wounds, these
were treated correspondingly. The intervention and control
treatment were applied in an open-label fashion.
Dressings were changed based on the study flow chart
every 24 to 48 hours until the end of treatment at day 14.
In case of delayed wound healing (wound present > 6 weeks
at initiation of study treatment), the treatment period was
prolonged until day 28.
2.3. Outcome Assessment. Before the start of treatment and at
every dressing change, photographs of the respective wounds
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Figure 3: Disposition of patients.
were taken.We used a Canon camera, EOSDigital SLR series,
and our in-house wound measuring system, which allowed
outer tracing of wound borders and calculation of wound
surface.
The imageswere uploaded into the electronicCaseReport
Form (eCRF), cropped to remove pen markings at the
treatment side, and coded for blinding. The (open) wound
surface area (in cm2) was recorded on day 0 and at each
dressing change until the end of the treatment period at day
14/day 28. These data enabled us to calculate the percentage
of reepithelialization. Two independent experts evaluated
treatment efficacy in a blinded fashion based on comparing
chronological series of cropped wound photographs taken
before the start of treatment, during wound dressing changes,
and at the end of treatment on day 14/day 28 and choosing
the series with signs of better reepithelialization. Remote
photographic analysis has been shown to be a reliablemethod
of wound evaluation [36].
The degree of reepithelialization was calculated as the
ratio of reepithelialized wound area relative to the initial
wound area.
At each dressing change, severity of touch sensitivity and
itch of each treatment area were examined and rated on a
visual analog scale from 1 to 10. Accordingly, patients or
their legal representatives were asked to provide feedback
on tolerability and efficacy of the intervention and control
treatment. The amount of exudate was rated as low, middle,
or strong.
2.4. Primary Outcome. All wound photographs were sum-
marized within chronological series of even orientation and
size by patient and wound. The 2 blinded experts were asked
to evaluate reepithelialization of the wound pairs for each
series and to decide which part of the wound reepithelialized
faster than the other or if there was an equal degree of
reepithelialization in both parts of the wound pair.
2.5. Secondary Outcomes. Secondary efficacy variables of
the study were percentage of wound epithelialization as
measured and documented at each dressing change. The
degree of reepithelializationwas calculated for each wound as
the ratio of reepithelialized area to initial open wound area.
Wounds were considered closed if they were at least 95%
epithelialized.
Additionally, we evaluated the extent of touch sensitivity,
itch, exudation, and the assessment of efficacy and tolerance
given by the investigators and patients or their legal represen-
tatives.
Secondary safety variables of the study were all adverse
events, treatment-related or not, graded according to the
NCI-CTC grading system on a 4-point scale (mild, moderate,
severe, and life-threatening) and assessment of tolerability by
the investigators and patients and/or their legal representa-
tives.
2.6. Statistical Considerations. A sample size calculation was
not performed, as the planned number of patients eligible
for enrollment into this pilot study was limited. Statisti-
cal analyses on the primary outcome parameter of faster
reepithelialization were performed using a two-sided exact
binomial test with a significance level of 𝑝 = 0.05 against the
null hypothesis of no difference between treatments. For the
secondary outcome variable of the amount of reepithelializa-
tion, we applied Wilcoxon signed-rank test.
3. Results
3.1. Patient Data. 10 patients were enrolled in the study. As 2
patients participated in a second cycle of treatment, 12 wound
pairs were evaluated. None of the patients was lost to follow-
up or dropped out (Figure 3): all patients who qualified for
the inclusion criteria suffered from dystrophic EB, 9 patients
had recessive dystrophic EB (RDEB), one had intermediate
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generalized RDEB, 8 had severe generalized RDEB, and 1
had localized dominant dystrophic EB. Expression of colla-
gen VII and/or mutations of COL7A1 were determined as
summarized in Table 1. The median age of patients was 20
years (range: 6–48 years).No infant screened during the study
period showed large enough wounds enabling participation.
3.2. Wounds. Nine of 12 wound pairs (75.0%) analyzed in
the study were present in less than 6 weeks. 3 of 12 wound
pairs (25%) were chronic, showing no tendency to heal for
more than 6 weeks. The mean wound size was 17.5 cm2
in the intervention group (7.3–45 cm2) versus 17.7 cm2 in
the control group (6.3–45 cm2). In 7 cases, large wounds
were chosen and divided into two halves for comparative
treatment. In the other 5 cases, 2 comparable wounds were
identified, where one was treated with Oleogel-S10 and the
other with nonadhesive wound dressing alone (Table 2). All
patients followed the study protocol except for one patient,
whose wound was additionally treated with an antiseptic
gel (polyhexanide 0.04%, Lavasept) on both areas for the
duration of 3 dressing changes towards the end of the study
due to a suspected superinfection.
3.3. Reepithelialization. In 5 of 12 cases (41%), the interven-
tion wound was rated as better epithelialized unanimously
by both independent reviewers. In another 3 of 12 cases, 1
reviewer rated epithelialization of the intervention wound as
superior whereas the other expert considered the wounds
as healing equally well. In the remaining 4 cases, either
epithelialization was considered as equal or the result was
controversial (Table 3). Thus, the comparison of unanimous
“winners” was 5 versus 0 (𝑝 = 0.063, binomial test) in favor
of Oleogel-S10 compared to standard-of-care treated wound
halves.
3.4. Secondary Outcomes. Measurement of wound sizes sug-
gested a trend towards faster closure of wounds that had been
treated with Oleogel-S10 both on day 7 and on day 14. On
day 7 (±1), the median epithelialization of the initial wound
surface was 69.7% (intervention) versus 57.4% (control) and
on day 14 was 87.7% (intervention) versus 79.2% (control)
(𝑝 = 0.21 on day 7; 𝑝 = 0.33 on day 14, Wilcoxon test,
Figure 4).
Wound closure with at least 95% epithelialization was
reached in 5 of 12 wounds in the Oleogel-S10 group versus 2
of 12 in the control group. The mean time for wound closure
was 10.5 days in the intervention group versus 14 days in the
control group (Figure 5).
As can be expected in EB patients, we experienced
retraumatization of wounds with an increase of wound size
≥5% compared with the preceding measurement in 7 of 12
wound pairs. In 3 wound pairs, it occurred on both sides, the
intervention and the control wound. Additionally, it occurred
in another 3 intervention and 1 control wound halves. As this
made the evaluation of reepithelialization more difficult, we
looked at the epithelialization of all wounds at one follow-
up prior to retrauma and compared the mean percentage of
epithelialization at this point, which was 78% for Oleogel-
S10 versus 73% for the control. There was an advance of
epithelialization by ≥10% in 5 of 12 cases for Oleogel-S10 as
opposed to 2 of 12 cases for the control.
Patients’ assessment of tolerability of Oleogel-S10 and
standard treatmentwas considered as good (97.4%) or accept-
able (2.6%) in the intervention and as good in 100% of
the control group. Patients reported treatment with Oleogel-
S10 more frequently as efficient (75.3%) than with standard
dressings alone (53.3%). The application of Oleogel-S10 was
easy. The substance was tolerated very well without any
complaints of stinging or burning.
We did not find any relevant differences in the perception
of touch sensitivity, itch, and amount of exudate between
intervention and control arms.
4. Discussion
In this phase II pilot study, we investigated the effects of
Oleogel-S10 on wounds of patients suffering from dystrophic
EB. Both the evaluation of two blinded experts and the
percentage of epithelialization measured by the investigators
were consistent and suggested a trend towards faster healing
of wounds when treated with Oleogel-S10 combined with
nonadhesive dressings versus standard wound care with
the dressings alone. The number of healed wounds (≥95%
epithelialization) was higher and the mean time needed for
wound closure was shorter in the intervention than in the
control group. Likely owing to the relatively low number of
10 patients, however, these results did not reach statistical
significance.
The results of this pilot trial showed feasibility of study
procedures and call for larger randomized controlled trials to
confirm the promising effects of Oleogel-S10 application in
EB wounds.
Recruitment of patients was achieved within the sched-
uled period and patients were compliant, cooperative, and
motivated to fulfil this study. Also, the duration of the study
between 2 and 4 weeks was feasible for all patients. None of
them dropped out or was lost to follow-up, which proved the
good tolerability of the product and the great need for new
therapeutic measures to treat wounds in patients with EB.
However, healing of large wounds exceeded the anticipated 4
weeks, which led to a rather lownumber of fully epithelialized
wounds after the completed study period of 2 and 4 weeks.
Tolerability of the study medication was very good. We
did not experience any local or generalized irritability or
contact sensitization towards either of the two components
of Oleogel-S10. Certainly, any medically active ingredient
has the potential for allergic sensitization, especially when
applied onto openwounds.Therefore, in patients with known
sunflower seed allergy, Oleogel-S10 should be used with
caution.
According to the study protocol, we included the first 10
patients willing to participate in the study. As the majority of
patients who present at our center suffer from dystrophic EB,
we included only this EB subtype in our study. This allowed
a more homogenous study population sharing characteristic
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Table 2: Wound characteristics.
Patient data Wound characteristics
Number Age(years) Gender Type of EB
Wound
number Type Location Age of wound
1 6 M RDEB(SG) 1 Large divided Lower extremity Recent
2 10 F RDEB(SG) 1 Large divided Lower extremity Recent
3 16 F RDEB(SG) 1 Large divided Upper extremity Recent
4 9 M RDEB(SG) 1 Large divided Lower extremity Chronic
5 36 M RDEB(SG) 1 Large divided Upper extremity Recent
6 47 F RDEB(GI) 1 Separate Trunk Chronic
7 21 M DDEB(loc.) 1 Large divided Lower extremity Recent
8 28 M RDEB(SG) 1 Separate Trunk Chronic
9 20 M RDEB(SG) 1 Separate Trunk Recent
9 20 M RDEB(SG) 2 Separate Trunk Recent
10 17 M RDEB(SG) 1 Large divided Trunk Recent
10 17 M RDEB(SG) 2 Large divided Lower extremity Recent
EB: epidermolysis bullosa; DDEB: dominant dystrophic EB; RDEB: recessive dystrophic EB; SG: severe generalized; GI: generalized intermediate; loc.: localized;
recent: less than 6 weeks; chronic: longer than 6 weeks.
Table 3: Results of blinded efficacy evaluation by patient and wound.
Number Reviewer 1 Reviewer 2 Unanimous “winner”
Oleogel-S10 Wound dressing
1 Control Oleogel-S10 — —
2 Oleogel-S10 Equal — —
3 Oleogel-S10 Oleogel-S10 1 —
4 Oleogel-S10 Equal — —
5 Equal Equal — —
6 Oleogel-S10 Oleogel-S10 1 —
7 Equal Equal — —
8 Oleogel-S10 Control — —
9 (1) Oleogel-S10 Oleogel-S10 1 —
9 (2) Equal Oleogel-S10 — —
10 (1) Oleogel-S10 Oleogel-S10 1 —
10 (2) Oleogel-S10 Oleogel-S10 1 —
Control = nonadhesive wound dressing.
traits of this rare disorder. However, it is possible that our
results are not applicable to other EB types.
Dystrophic EB causes major morbidity for the affected
individuals leading tomultiple secondary complications such
as anemia and deficiencies of iron, zinc, vitamins, and
micronutrients that impair wound healing. Therefore, the
intraindividual control, comparing wounds or wound halves
of the same individual, was a suitable approach, eliminating
confounding factors.
When planning the study, we chose to compare Oleogel-
S10 to standard treatment instead of using the vehicle,
respectively, placebo, as control. Apart from betulin extract,
the only other ingredient of Oleogel-S10 is sunflower oil
(SFO) which, other than Oleogel-S10, does not stay in the
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Figure 5: Complete wound closure of the intervention wound at day 13 of treatment.
allocated wound half due to its liquid consistency. Also, in
recent studies, a significantly better effect on wound healing
of Oleogel-S10 as opposed to both SFO and SFO with ethyl
cellulose has been demonstrated [32]. The use of pure SFO
has, as have the large majority of pure oils, even shown a
mild negative effect on wound healing as opposed to control
making pure SFO a less promising candidate as control than
standard wound care.
5. Conclusion
Oleogel-S10 is a topical gel made of pure sunflower oil and a
10% triterpene extract from birch bark. We used Oleogel-S10
on acute and chronic wounds (>6 weeks) in 10 patients with
dystrophic EB.
The results of the present study were promising and
provided reason for further investigations of the effects of
Dermatology Research and Practice 9
Oleogel-S10. Larger studies using Oleogel-S10 for wounds of
patients with all different forms of EB are needed to clarify
the effectiveness and safety in EB in general.
Concurrent to additional clinical studies with Oleogel-
S10, further insights into the anticarcinogenic effects of
betulin on human SCC cells, ideally coming fromEBpatients,
are needed. The anticarcinogenic effect, if proven to be real,
in combination with wound healing effects would make
Oleogel-S10 an ideal substance to use in EB wounds at early
stages, especially in severe generalized RDEB, the subtype
with the highest number of aggressive and metastasizing
SCCs.
The above-mentioned additional studies would help to
identify the optimal indications for use of Oleogel-S10 and
to clarify whether it can stand up to its promises.
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